Abstract
We describe the development and implementation of competitive fluorescence polarization (FP) based assays for determining activity of phosphoinositide 3-kinase (PI 3-K) and the type-II SH2-domaincontaining inositol 5-phosphatase (SHIP2). These assays are based on the interaction of specific phosphoinositide binding proteins with fluorophore-labeled phosphoinositide and inositol phosphate tracers. Enzyme reaction products are detected by their ability to compete with the fluorescent tracers for protein binding, leading to an increase in the amount of free tracer and a decrease in polarization (mP) values. A variety of fluorophore-labeled tracers were evaluated, and assay sensitivity and specificity for products of PI 3-K and SHIP2 activity was determined. Assay performance was evaluated using recombinant PI 3-Kα and SHIP2 with diC8-PI(4,5)P2 and diC8-PI(3,4,5)P3 as respective substrates. IC50 values for previously characterized PI 3-K inhibitors were within expected ranges. These assays are homogeneous, sensitive, and rapid, and suitable for HTS applications, and will facilitate screening for novel inhibitors of phosphoinositide kinases and phosphatases in drug development.
Keywords: competitive fluorescence, polarization assays, phosphoinositide 3-kinase, sh2-domaincontaining inositol 5-phosphatase
Combinatorial Chemistry & High Throughput Screening
Title: Competitive Fluorescence Polarization Assays for the Detection of Phosphoinositide Kinase and Phosphatase Activity
Volume: 6 Issue: 4
Author(s): Beth E. Drees, Amber Weipert, Heather Hudson, Colin G. Ferguson, Leena Chakravarty and Glenn D. Prestwich
Affiliation:
Keywords: competitive fluorescence, polarization assays, phosphoinositide 3-kinase, sh2-domaincontaining inositol 5-phosphatase
Abstract: We describe the development and implementation of competitive fluorescence polarization (FP) based assays for determining activity of phosphoinositide 3-kinase (PI 3-K) and the type-II SH2-domaincontaining inositol 5-phosphatase (SHIP2). These assays are based on the interaction of specific phosphoinositide binding proteins with fluorophore-labeled phosphoinositide and inositol phosphate tracers. Enzyme reaction products are detected by their ability to compete with the fluorescent tracers for protein binding, leading to an increase in the amount of free tracer and a decrease in polarization (mP) values. A variety of fluorophore-labeled tracers were evaluated, and assay sensitivity and specificity for products of PI 3-K and SHIP2 activity was determined. Assay performance was evaluated using recombinant PI 3-Kα and SHIP2 with diC8-PI(4,5)P2 and diC8-PI(3,4,5)P3 as respective substrates. IC50 values for previously characterized PI 3-K inhibitors were within expected ranges. These assays are homogeneous, sensitive, and rapid, and suitable for HTS applications, and will facilitate screening for novel inhibitors of phosphoinositide kinases and phosphatases in drug development.
Export Options
About this article
Cite this article as:
Drees E. Beth, Weipert Amber, Hudson Heather, Ferguson G. Colin, Chakravarty Leena and Prestwich D. Glenn, Competitive Fluorescence Polarization Assays for the Detection of Phosphoinositide Kinase and Phosphatase Activity, Combinatorial Chemistry & High Throughput Screening 2003; 6 (4) . https://dx.doi.org/10.2174/138620703106298572
DOI https://dx.doi.org/10.2174/138620703106298572 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Thyroid Function and Obesity: From Mechanisms to the Benefits of Levothyroxine in Obese Patients
Endocrine, Metabolic & Immune Disorders - Drug Targets Tetrazole Derivatives as Promising Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Computer-Aided Drug Design Applied to Secondary Metabolites as Anticancer Agents
Current Topics in Medicinal Chemistry The Molecular Basis of Notch Signaling Regulation: A Complex Simplicity
Current Molecular Medicine Wnt/beta-Catenin Signaling and Small Molecule Inhibitors
Current Pharmaceutical Design Amygdalin Decreases Adhesion and Migration of MDA-MB-231 and MCF-7 Breast Cancer Cell Lines
Current Molecular Pharmacology Progress in the Discovery of Polo-like Kinase Inhibitors
Current Topics in Medicinal Chemistry Promotion of Cervical Cancer Cell Proliferation by miR-130b Expression Level Changes and Inhibition of its Apoptosis by Targeting CDKN1A Gene
Current Cancer Drug Targets Inhibiting TLR9 Signaling Stimulates Apoptosis and Cell Cycle Arrest, and Alleviates Angiogenic Property in Human Cervical Cancer Cells
Endocrine, Metabolic & Immune Disorders - Drug Targets Selenosemicarbazone Metal Complexes as Potential Metal-based Drugs
Current Medicinal Chemistry A Retrospective Study on <i>Gloriosa superba</i> and Its Main Active Constituents
The Natural Products Journal Evidence for Epigenetic Alterations in Turner Syndrome Opens up Feasibility of New Pharmaceutical Interventions
Current Pharmaceutical Design Seocalcitol (EB 1089) A Vitamin D Analogue of Anti-cancer Potential. Background, Design, Synthesis, Pre-clinical and Clinical Evaluation
Current Pharmaceutical Design Alphavirus Vectors for Gene Therapy Applications
Current Gene Therapy Natural Antibodies: Protecting Role of IgM in Glioblastoma and Brain Tumours
Current Pharmaceutical Design Oncolytic Adenovirus: Preclinical and Clinical Studies in Patients with Human Malignant Gliomas
Current Gene Therapy The Medical Implications of Gastrointestinal Vagal Afferent Pathways in Nausea and Vomiting
Current Pharmaceutical Design A Comprehensive Study of Pharmacological Behaviors, Nano-Formulations, and Applications of Rosemary
The Natural Products Journal Use of Radiopharmaceuticals for Diagnosis, Treatment, and Follow-Up of Differentiated Thyroid Carcinoma
Anti-Cancer Agents in Medicinal Chemistry HDAC Inhibitors as Novel Anti-Cancer Therapeutics
Recent Patents on Anti-Cancer Drug Discovery